Actively Recruiting
OUD (Opioid Use Disorder) Target Trial
Led by Duke University · Updated on 2026-01-09
80
Participants Needed
1
Research Sites
95 weeks
Total Duration
On this page
Sponsors
D
Duke University
Lead Sponsor
S
Stanford University
Collaborating Sponsor
AI-Summary
What this Trial Is About
In this research study the investigators will work with 80-participants with opioid use disorder who are starting treatment with the medication buprenorphine and are trying to quit using opioids. The investigators are trying to learn two things: 1. Can an MRI brain marker be used to predict which participants will be successful in quitting opioids with buprenorphine? 2. Does adjunctive treatment with repetitive Transcranial Magnetic Stimulation (rTMS) help people quit using opioids more than a sham (placebo) version of rTMS? In order to complete the study the investigators will ask participants to: * Complete an MRI within 5-days of starting buprenorphine and again after they are on a full stable dose 1-3 weeks later. * Undergo study-treatment with 30-sessions of either real or placebo rTMS in as little as 1-week (10-sessions-per-day for five days) or as long as over 6-weeks. * Meet with the investigators once per week over the following 12-weeks to see if the participants have been able to quit using opioids over that time.
CONDITIONS
Official Title
OUD (Opioid Use Disorder) Target Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 or older; all genders included.
- Intellectual ability sufficient to provide informed consent and complete assessments (English speaking/writing).
- Meet DSM-5 criteria for moderate or severe opioid use disorder.
- May have other substance use disorders except alcohol or sedative/hypnotic; opioids must be primary substance.
- Starting buprenorphine treatment and planning opioid abstinence.
You will not qualify if you...
- Pregnant, breastfeeding, or planning pregnancy.
- Alcohol or sedative/hypnotic use disorders due to seizure risk.
- History of or current psychotic disorders such as schizophrenia.
- Current or past bipolar disorder.
- Unstable Axis-I condition requiring new medication.
- Active suicidal thoughts or attempts within last 90 days.
- History of or current dementia or cognitive impairment.
- Contraindications to rTMS or MRI (e.g., implanted metal, seizure risk, implanted devices).
- Unstable general medical conditions.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Duke University
Durham, North Carolina, United States, 27705
Actively Recruiting
Research Team
G
Gregory Sahlem
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here